98PD - Exon 20 mutations of the epidermal growth factor receptor (EGFR) in lung adenocarcinomas: clinicopathologic factors and response to therapy
|Date||28 March 2014|
|Session||Poster Discussion 2|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
J. Naidoo1, C.S. Sima2, M.D. Hellmann1, M.E. Arcila3, N.A. Rizvi1, H.A. Yu1
EGFR exon 20 insertions or point mutations in EGFR S768 or R776 represent 10-15% of mutations in EGFR. It is unclear whether their presence predicts response to EGFR tyrosine kinase inhibitors (TKI).